Who is sponsoring NCT04638959?

NCT04638959 is sponsored by Shanghai Jiao Tong University School of Medicine.

What drugs are being tested in NCT04638959?

Interventions in NCT04638959: collect gastric tissue and stool samples.

Is NCT04638959 still recruiting?

NCT04638959 is currently status unknown. Last updated 20 November 2020.

Last reviewed 2020-11-20 · How we verify

NCT04638959

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Faecal Bacteria Detection in Early Screening and Diagnosis of GC

Status unknown Last updated 20 November 2020

What this trial tests

trial testing collect gastric tissue and stool samples in Non-invasive and Sensitive Faecal Bacterial Markers for Early Screening and Diagnosis of Gastric Cancer in 1,100 participants. Status unknown.

Timeline

30 September 2019

Primary endpoint
31 March 2021

30 September 2021

Quick facts

Lead sponsor	Shanghai Jiao Tong University School of Medicine
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	1,100
Start date	30 September 2019
Primary completion	31 March 2021
Estimated completion	30 September 2021
Sites	10 locations across China

Drugs / interventions tested

collect gastric tissue and stool samples

Conditions studied

Non-invasive and Sensitive Faecal Bacterial Markers for Early Screening and Diagnosis of Gastric Cancer — all drugs for Non-invasive and Sensitive Faecal Bacterial Markers for Early Screening and Diagnosis of Gastric Cancer →

Sponsor

Shanghai Jiao Tong University School of Medicine

Who can join

Adults 40 to 75, any sex, with Non-invasive and Sensitive Faecal Bacterial Markers for Early Screening and Diagnosis of Gastric Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this clinical trial, we aim to explore the synergistic alteration of specific bacteria both in gastric mucosas and feces of gastric cancer patients for the method of non-invasive and cost-effective faecal marker detection. We aim to select and validate specific microbes as noninvasive, accurate, simple, sensitive and highly-accepted biomarkers that might assist to screen and diagnose gastric cancer, especially early gastric cancer patients.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Fecal Signatures of Streptococcus anginosus and Streptococcus constellatus for Noninvasive Screening and Early Warning of Gastric Cancer.
Zhou CB, Pan SY, Jin P, Deng JW, et al · · 2022 · cited 83× · PMID 35167866 · DOI 10.1053/j.gastro.2022.02.015
Interdisciplinary insights into the link between gut microbiome and gastric carcinogenesis-what is currently known?
Kaźmierczak-Siedlecka K, Daca A, Roviello G, Catalano M, et al · · 2022 · cited 28× · PMID 34741681 · DOI 10.1007/s10120-021-01260-y

Verify or expand the search:

Other Shanghai Jiao Tong University School of Medicine trials

Trials by the same sponsor.

NCT07570810 — Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM · NA · not yet recruiting
NCT07528079 — Organoid-based Sensitivity-guided Chemotherapy for Advanced / Refractory Pediatric Tumors · NA · enrolling by invitation
NCT07535710 — Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-ce · Phase 1, PHASE2 · not yet recruiting
NCT07535762 — Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T · Phase 2 · not yet recruiting
NCT07350057 — A Preliminary Clinical Study on the Efficacy of Cyclophosphamide and Sirolimus Combined With VIC-1911 in Preventing Graf · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04638959 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Jiao Tong University School of Medicine
Last refreshed: 20 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04638959.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing